Global Statistics

All countries
548,935,393
Confirmed
Updated on June 26, 2022 8:18 pm
All countries
520,730,887
Recovered
Updated on June 26, 2022 8:18 pm
All countries
6,350,765
Deaths
Updated on June 26, 2022 8:18 pm
Sunday, August 14, 2022

Global Statistics

All countries
548,935,393
Confirmed
Updated on June 26, 2022 8:18 pm
All countries
520,730,887
Recovered
Updated on June 26, 2022 8:18 pm
All countries
6,350,765
Deaths
Updated on June 26, 2022 8:18 pm
Molderizer and Safe Shield

Pharmac to fund two new Covid drugs – for immune-compromised and high risk people

Davis residents can now view local COVID-19 rates, tracked via wastewater testing

Healthy Central Valley Together is now conducting COVID-19 wastewater testing in Davis    By SYDNEY AMESTOY — campus@theaggie.org   Davis residents, as well as residents in some...

Researchers Pinpointed Covid-19’s Origin to Within a Few Metres

Australia's public broadcaster interviewed a virologist who "played a key role in mapping the evolution of COVID-19" (and was also "the first...

Did it work? The elusive impact of a $45 million state grant to grow jobs

In 2017, Maine voters approved borrowing $45 million to pay for private sector development, encouraged by the promise of new jobs and economic...

Panadol Cough & Cold, Decolgen in short supply as more Covid-19 patients self-medicate

SINGAPORE - Some over-the-counter medicine to treat fever, cough and cold are in short supply at pharmacies here, as more Covid-19 patients opt to...


Pharmac has secured 2,300 of a monoclonal antibody treatment, sotrovimab, with proposed access for severely immunocompromised people.

GlaxoSmithKline

Pharmac has secured 2,300 of a monoclonal antibody treatment, sotrovimab, with proposed access for severely immunocompromised people.

Pharmac is set to roll out two new Covid-19 drugs for immunocompromised people, including one that’s designed to be taken before people are exposed to the virus.

The drugs, both monoclonal antibodies or ‘mabs’, target the spike protein on the virus, which is what enters human cells. Both drugs are given via injection.

Neither are in the country, and both are yet to be approved by MedSafe, but applications are underway.

One is tixagevimab with cilgavimab – which Pharmac is proposing to fund as a pre-exposure prophylaxis for severely immunocompromised people before they become infected with Covid-19. It’s the first preventative Covid-19 treatment to be funded, other than the vaccines, Pharmac’s director of operations Lisa Williams said.

READ MORE:
* Covid-19: 30,000 courses of new preventative oral antiviral drug arrive in Auckland
* Covid-19: Pfizer’s oral treatment arrives, will be available next week
* Pharmac criticised over delayed delivery of antiviral drug to treat Covid-19

This drug is being assessed by MedSafe, under an abbreviated application process.

If approved, it’s expected to be available this year for people who meet the access criteria.

Pharmac has secured an initial 20,000 courses of tixagevimab through the drug supplier, AstraZeneca, with the option to purchase an additional 20,000 courses.

Pharmac has also signed an advance purchase agreements for the second drug, sotrovimab for 2300 courses, which is expected to be delivered to New Zealand in a single shipment, Williams said.

STUFF

Prime Minister Jacinda Ardern announces the Government has bought 60,000 courses of the new Pfizer antiviral drug to fight Covid-19. (Video first published Dec 6, 2021)

“We want to ensure our access criteria are ready to be put into action as soon as these treatments are approved by MedSafe and delivered New Zealand,” Williams said.

Pharmac was setting access criteria to ensure the medicines reach those with the highest health need and those most likely to benefit from the treatment, Williams said.

“Through our consultation process, we ask health professionals and stakeholders, including consumer groups and any other interested parties, for their feedback on the access criteria we are proposing.”

As more stock of tixagevimab arrived in New Zealand, Pharmac would consider widening access to include the next most at risk group of people, such as moderately immunocompromised New Zealanders, Williams said.

The consultation is available on Pharmac’s website for anyone wanting to have a say.



Source link

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Popular

Davis residents can now view local COVID-19 rates, tracked via wastewater testing

Healthy Central Valley Together is now conducting COVID-19 wastewater testing in Davis    By SYDNEY AMESTOY — campus@theaggie.org   Davis residents, as well as residents in some...

Researchers Pinpointed Covid-19’s Origin to Within a Few Metres

Australia's public broadcaster interviewed a virologist who "played a key role in mapping the evolution of COVID-19" (and was also "the first...

Did it work? The elusive impact of a $45 million state grant to grow jobs

In 2017, Maine voters approved borrowing $45 million to pay for private sector development, encouraged by the promise of new jobs and economic...

Related Articles

Davis residents can now view local COVID-19 rates, tracked via wastewater testing

Healthy Central Valley Together is now conducting COVID-19 wastewater testing in Davis    By SYDNEY AMESTOY — campus@theaggie.org   Davis residents, as well as residents in some...

Researchers Pinpointed Covid-19’s Origin to Within a Few Metres

Australia's public broadcaster interviewed a virologist who "played a key role in mapping the evolution of COVID-19" (and was also "the first...

Did it work? The elusive impact of a $45 million state grant to grow jobs

In 2017, Maine voters approved borrowing $45 million to pay for private sector development, encouraged by the promise of new jobs and economic...